Evidence map›Paper›PMID 15273142›Full record

ArticleAntimicrobial agents and chemotherapy2004

In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations.

David J Farrell, Ian Morrissey, Sarah Bakker, Sylvie Buckridge, David Felmingham

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed.

  1. Article
  2. Article
  3. The macrolide antibiotic renaissance.British journal of pharmacology · 2017
    Review
  4. Article
  5. Article
  6. Resistance to Macrolide Antibiotics in Public Health Pathogens.Cold Spring Harbor perspectives in medicine · 2016
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Linezolid-resistant Staphylococcus cohnii, Greece.Emerging infectious diseases · 2009
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

David J FarrellGR Micro Ltd., London, United Kingdom. D.Farrell@grmicro.co.uk
Ian Morrissey
Sarah Bakker
Sylvie Buckridge
David Felmingham

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To date, 86 of 7,746 macrolide-resistant Streptococcus pneumoniae isolates from 1999 to 2002 PROTEKT (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin) surveillance studies were negative for methylase and efflux mechanisms. Mutations in 23S rRNA or the genes encoding riboprotein L4 or L22 were found in 77 of 86 isolates. Six isolates were resistant to quinupristin-dalfopristin and two were resistant to linezolid, while telithromycin demonstrated good activities against all isolates.

Indexed as

KetolidesAcetamidesAnti-Bacterial AgentsDose-Response Relationship, DrugDrug Resistance, BacterialHumansLinezolidMacrolidesMutationOxazolidinonesPneumococcal InfectionsRibosomesRNA, Ribosomal, 23SStreptococcus pneumoniaeVirginiamycinAcetamidesAnti-Bacterial AgentsKetolidesLinezolidMacrolidesOxazolidinonesquinupristin-dalfopristinRNA, Ribosomal, 23StelithromycinVirginiamycin

Identifiers

PMID15273142
PMCPMC478535

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.